Law360, New York (November 21, 2011, 5:38 PM ET) -- Actelion Ltd. plans to appeal a reduced $415 million verdict against it in a suit claiming it bought CoTherix Inc. in order to nix a drug licensing deal and preserve its monopoly on a hypertension treatment, the company said Monday.
A California state jury awarded Asahi $577 million in May after a three-month trial in the suit, brought by Asahi Kasei Pharma Corp., and Superior Court Judge Marie S. Weiner reduced the award by $70 million in July to offset a payment made by CoTherix in...
Actelion To Appeal $415M Verdict Over CoTherix Buy
To view the full article, take a free trial now.
